HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Enhanced anti-HCV activity of interferon alpha 17 subtype.

AbstractBACKGROUND:
Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. So, it is interesting to improve the treatment efficacy. Interferon alpha is a type I interferon composed of 12 different subtypes. Each subtype signals by the Jak-Stat pathway but modulations in the antiviral activity was previously described.
METHODS:
Using the hepatitis C virus (HCV) culture system, we have tested the anti-HCV activity of each interferon alpha subtypes. We have analyzed the effect of each subtype on the HCV multiplication and the cell-signaling pathway for some subtypes.
RESULTS:
There were divergent effects of IFN alpha subtypes against HCV. We have found that IFN alpha 17 was three times more efficient than IFN alpha 2a on HCV. This efficiency was related to a stronger stimulation of the Jak-Stat pathway.
CONCLUSION:
We suggest that IFN alpha17 should be tested therapeutically with a view to improving treatment efficacy.
AuthorsAurelie Dubois, Catherine François, Veronique Descamps, Carole Fournier, Czeslaw Wychowski, Jean Dubuisson, Sandrine Castelain, Gilles Duverlie
JournalVirology journal (Virol J) Vol. 6 Pg. 70 ( 2009) ISSN: 1743-422X [Electronic] England
PMID19493343 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • IFNA17 protein, human
  • Interferon-alpha
Topics
  • Antiviral Agents (pharmacology)
  • Cell Line
  • Hepacivirus (drug effects)
  • Hepatocytes (virology)
  • Humans
  • Interferon-alpha (pharmacology)
  • Microbial Sensitivity Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: